The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis
Abstract
Two prior double‐blind, placebo‐controlled, randomized trials demonstrated that glatiramer acetate (GA) reduces relapse rates in patients with relapsing remitting multiple sclerosis (RRMS). This study was designed to determine the effect, onset, and durability of any effect of GA on disease activity monitored with magnetic resonance imaging (MRI) in patients with RRMS. Two hundred thirty‐nine eligible patients were randomized to receive either 20 mg GA (n = 119) or placebo (n = 120) by daily subcutaneous injection. Eligibility required one or more relapses in the 2 years before entry and at least one enhancing lesion on a screening MRI. The study was a randomized, double‐blind, placebo‐controlled phase during which all patients studied underwent monthly MRI scans and clinical assessments over 9 months. The primary outcome measure was the total number of enhancing lesions on T1‐weighted images. Secondary outcome measures included the proportion of patients with enhancing lesions, the number of new enhancing lesions and change in their volume; the number of new lesions detected on T2‐weighted images and change in their volume, and the change in volume of hypointense lesions seen on unenhanced T1‐weighted images. Clinical measures of disease activity were also evaluated. The active treatment and placebo groups were comparable at entry for all demographic, clinical, and MRI variables. Treatment with GA showed a significant reduction in the total number of enhancing lesions compared with placebo (−10.8, 95% confidence interval −18.0 to −3.7; p = 0.003). Consistent differences favoring treatment with GA were seen for almost all secondary end points examined: number of new enhancing lesions (p < 0.003), monthly change in the volume of enhancing lesions (p = 0.01), and change in volume (p = 0.006) and number of new lesions seen on T2‐weighted images (p < 0.003). The relapse rate was also significantly reduced by 33% for GA‐treated patients (p = 0.012). All effects increased over time. Glatiramer acetate significantly reduced MRI‐measured disease activity and burden. Ann Neurol 2001;49:290–297
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. M., Fischer, J. S., Goodkin, D. E., Granger, C. V., Simon, J. H., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410390304 · Cited by 2,450
Ebers, G. C. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03334-0 · Cited by 2,073
Johnson, K. P., Brooks, B. R., Cohen, J. A., Ford, C. C., Goldstein, J., Lisak, R. P., Myers, L. W., Panitch, H. S., Rose, J. W., Schiffer, R. B., et al. (1995) · Neurology · doi:10.1212/wnl.45.7.1268 · Cited by 1,898
Self-citationHauser, S. L., Dawson, D. M., Lehrich, J. R., Beal, M. F., Kevy, S. V., Propper, R. D., Mills, J. A., & Weiner, H. L. (1983) · New England Journal of Medicine · doi:10.1056/nejm198301273080401 · Cited by 827
Johnson, K. P., Brooks, B. R., Cohen, J. A., Ford, C. C., Goldstein, J., Lisak, R. P., Myers, L. W., Panitch, H. S., Rose, J. W., Schiffer, R. B., et al. (1998) · Neurology · doi:10.1212/wnl.50.3.701 · Cited by 509
Self-citationKappos, L., Moeri, D., Radue, E. W., Schoetzau, A., Schweikert, K., Barkhof, F., Miller, D., Guttmann, C. R., Weiner, H. L., Gasperini, C., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)03053-0 · Cited by 499
Self-citationA Pilot Trial of Cop 1 in Exacerbating–Remitting Multiple Sclerosis
Bornstein, M. B., Miller, A., Slagle, S., Weitzman, M., Crystal, H., Drexler, E., Keilson, M., Merriam, A., Wassertheil-Smoller, S., Spada, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198708133170703 · Cited by 462
Miller, D. H., Albert, P. S., Barkhof, F., Francis, G., Frank, J. A., Hodgkinson, S., Lublin, F. D., Paty, D. W., Reingold, S. C., & Simon, J. (1996) · Annals of Neurology · doi:10.1002/ana.410390104 · Cited by 444
Duda, P. W., Schmied, M. C., Cook, S. L., Krieger, J. I., & Hafler, D. A. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8970 · Cited by 416
Natural history of multiple sclerosis
Weinshenker, B. G. (1994) · Annals of Neurology · doi:10.1002/ana.410360704 · Cited by 405
Katz, D., Taubenberger, J. K., Cannella, B., McFarlin, D. E., Raine, C. S., & McFarland, H. F. (1993) · Annals of Neurology · doi:10.1002/ana.410340507 · Cited by 387
Miller, D. H., Barkhof, F., Berry, I., Kappos, L., Scotti, G., & Thompson, A. J. (1991) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.54.8.683 · Cited by 370
Hohlfeld, R. (1997) · Brain · doi:10.1093/brain/120.5.865 · Cited by 365
Magnetic resonance studies of intramuscular interferon β–1a for relapsing multiple sclerosis
Simon, J. H., Jacobs, L. D., Campion, M., Wende, K., Simonian, N., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. M., et al. (1998) · Annals of Neurology · doi:10.1002/ana.410430114 · Cited by 330
Aharoni, R., Teitelbaum, D., Sela, M., & Arnon, R. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.20.10821 · Cited by 274
Stone, L. A., Frank, J. A., Albert, P. S., Bash, C., Smith, M. E., Maloni, H., & McFarland, H. F. (1995) · Annals of Neurology · doi:10.1002/ana.410370511 · Cited by 247
Fridkis-Hareli, M., Teitelbaum, D., Gurevich, E., Pecht, I., Brautbar, C., Kwon, O. J., Brenner, T., Arnon, R., & Sela, M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.11.4872 · Cited by 243
Miller, A., Shapiro, S., Gershtein, R., Kinarty, A., Rawashdeh, H., Honigman, S., & Lahat, N. (1998) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(98)00191-x · Cited by 225
Aharoni, R., Teitelbaum, D., Arnon, R., & Sela, M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.2.634 · Cited by 191
Bornstein, M. B., Miller, A., Slagle, S., Weitzman, M., Drexler, E., Keilson, M., Spada, V., Weiss, W., Appel, S., Rolak, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.533 · Cited by 173
Filippi, M., Horsfield, M. A., Adèr, H. J., Barkhof, F., Bruzzi, P., Evans, A., Frank, J. A., Grossman, R. I., McFarland, H. F., Molyneux, P., et al. (1998) · Annals of Neurology · doi:10.1002/ana.410430414 · Cited by 172
Self-citationRovaris, M., Filippi, M., Calori, G., Rodegher, M., Campi, A., Colombo, B., & Comi, G. (1997) · Journal of Neurology · doi:10.1007/s004150050083 · Cited by 158
Self-citationGlatiramer acetate (Copaxone) treatment in relapsing–remitting MS
Ge, Y., Grossman, R. I., Udupa, J. K., Fulton, J. C., Constantinescu, C. S., Gonzales–Scarano, F., Babb, J. S., Mannon, L. J., Kolson, D. L., & Cohen, J. A. (2000) · Neurology · doi:10.1212/wnl.54.4.813 · Cited by 137
Arnon, R. (1996) · Immunology Letters · doi:10.1016/0165-2478(96)02506-0 · Cited by 108
Pozzilli, C., Bastianello, S., Koudriavtseva, T., Gasperini, C., Bozzao, A., Millefiorini, E., Galgani, S., Buttinelli, C., Perciaccante, G., Piazza, G., et al. (1996) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.61.3.251 · Cited by 106
Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis
Barkhof, F., Filippi, M., van Waesberghe, J. H., Molyneux, P. D., Rovaris, M., Nijeholt, G. J. L. À., Tubridy, N. J., Miller, D. H., Yousry, T. A., Radue, E. W., et al. (1997) · Neurology · doi:10.1212/wnl.49.6.1682 · Cited by 103
Self-citationEffect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis
Mancardi, G., Sardanelli, F., Parodi, R. C., Melani, E. F., Capello, E., Inglese, M., Ferrari, A., Sormani, M. P., Ottonello, C., Levrero, F., et al. (1998) · Neurology · doi:10.1212/wnl.50.4.1127 · Cited by 94
Racke, M. K., Martinꝉ, R., McFarland, H. F., & Fritz, R. B. (1992) · Journal of Neuroimmunology · doi:10.1016/0165-5728(92)90157-g · Cited by 80
Filippi, M., Gawne-Cain, M. L., Gasperini, C., vanWaesberghe, J. H. T. M., Grimaud, J., Barkhof, F., Sormani, M. P., & Miller, D. H. (1998) · Neurology · doi:10.1212/wnl.50.1.238 · Cited by 79
Self-citationSperfeld (1999) · Pure Amsterdam UMC · doi:10.1002/1531-8249(199911)46:5 · Cited by 2
Cited by
Multiple Sclerosis: An Immune or Neurodegenerative Disorder?
Trapp, B. D., & Nave, K.-A. (2008) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.30.051606.094313 · Cited by 1,724
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
Brinkmann, V., Billich, A., Baumruker, T., Heining, P., Schmouder, R., Francis, G., Aradhye, S., & Burtin, P. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3248 · Cited by 1,273
A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Miller, D. H., Khan, O. A., Sheremata, W. A., Blumhardt, L. D., Rice, G. P. A., Libonati, M. A., Willmer-Hulme, A. J., Dalton, C. M., Miszkiel, K. A., & O'Connor, P. W. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020696 · Cited by 1,242
The clinico-radiological paradox in multiple sclerosis revisited
Barkhof, F. (2002) · Current Opinion in Neurology · doi:10.1097/00019052-200206000-00003 · Cited by 726
Metadata
- Authors
- Comi, G., Filippi, M., Wolinsky, J. S., & European/Canadian Glatiramer Acetate Study Group
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2001-03
- Volume
- 49
- Issue
- 3
- Pages
- 290-297
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W4366064463
- Cited by
- 650
- References
- 32
- FWCI
- 23.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.